TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02293551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Administered SC
Study: NCT04162678

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study: NCT02170766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study: NCT02805595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23.4% Hypertonic saline
Description: Saline Injections
Study: NCT02107872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02723175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
Study: NCT04596085

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Product - ViraCide
Description: Viracide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Starch Powder Soft gels
Description: Starch Powder Soft gels
Study: NCT00139256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Betamethasone injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betamethasone
Description: Betamethasone injection
Study: NCT02259985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itasetron tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itasetron tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itasetron infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study: NCT02577185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 9 mg/ml
Study: NCT00766974

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-embolism Knee High Stocking
Description: Anti-embolism Knee High Compression Stocking

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20-30 Knee High Compression Stocking
Description: 20-30 mmHg Knee High COmpression Stocking
Study: NCT01786460

Intervention type: OTHER
Intervention: Blood draw at Days 0, 7, 14, and 21
Study: NCT04405271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet
Description: Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of 1 tablet per day will be administered for a total of 12 weeks.
Study: NCT04409717

Intervention type: PROCEDURE
Intervention: Type II endoleak treatment
Description: Type II endoleak endovascular treatment
Study: NCT00661388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: sc every month (starting dose 1.2 micrograms/kg)
Study: NCT02094781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein and creatine supplement
Description: Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein only supplement
Description: Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
Study: NCT00721136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continue warfarin through the procedure
Description: The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continue warfarin through the procedure
Description: The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hold warfarin
Description: For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin held with heparin transition.
Description: For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
Study: NCT01749930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Timolol will be administered BID once in the morning and once in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOL-303259-X
Description: All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
Study: NCT03533192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: It's Your Game...Keep it Real
Description: It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
Study: NCT02067299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally on Day 1 of the appropriate treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally on Day 1 of the appropriate treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally on Day 1 of the appropriate treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
Study: NCT00631527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Injections given through a needle in the muscle every 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Subcutaneous injections given once every 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Starting dose of 12.5 mg by mouth daily for 4 weeks
Study: NCT02363322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/Current Standard of Care Plus ZMapp
Description: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A/Current Standard of Care Alone
Description: Optimized standard of care for Ebola virus infection
Study: NCT01028066

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
Study: NCT00930436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: Serum creatinine will be measured on Days 3,7, 30, 90, and 180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: Serum creatinine will be measured on Days 3,7, 30, 90, and 180
Study: NCT01431885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis by cervical length and fibronectin
Description: Diagnosis will be made by MOD Algorithm B

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cervical change
Description: Diagnosis will be made by digital examination of cervical change
Study: NCT04323293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Water Bath
Description: immersion of the hand for 2-5min in 2-10°C water

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral Water Bath
Description: immersion of the hand for 2-5min in 32±2°C water
Study: NCT00473525

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200 10 mg QD
Description: 10 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200 20 mg QD
Description: 20 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200 5 mg QD
Description: 5 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200 2 mg QD
Description: 2 mg QD
Study: NCT01092793

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill
Description: Encapsulated oil from the antarctic crustacean Krill

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Encapsulated, raffined cod-oil
Study: NCT00049595

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT04942223

Intervention type: DEVICE
Group type: OTHER
Intervention: guided bone regeneration
Description: After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
Study: NCT03530332

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PreTRM test
Description: Blood test to determine risk of preterm birth
Study: NCT04004403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate day fasting
Description: The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate day fasting
Description: The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
Study: NCT01180517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: balloon angioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: balloon angioplasty
Study: NCT00906958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexus Flow Generator
Description: The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VPAP Flow Generator 25
Description: Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
Study: NCT01150201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: For CKD treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Control
Study: NCT01860898

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Biopsy
Description: Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
Study: NCT04542720

Intervention type: PROCEDURE
Intervention: Observational: Decompression
Description: Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.

Intervention type: PROCEDURE
Intervention: Observational: Extension Fusion
Description: Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
Study: NCT02365415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 8 weeks oral sirolimus, following drug levels
Study: NCT03322423

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multifocal Contact Lens 1
Description: Dailies Total 1 Multifocal Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multifocal Contact Lens 1
Description: Dailies Total 1 Multifocal Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multifocal Contact Lens 2
Description: Biotrue ONEday for Presbyopia Contact Lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multifocal Contact Lens 2
Description: Biotrue ONEday for Presbyopia Contact Lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spherical Contact Lens 2
Description: BioTrue ONEDay Spherical

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spherical Contact Lens 2
Description: BioTrue ONEDay Spherical
Study: NCT01167868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FosD
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT00535821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Doppler monitoring - CardioQ, Deltex Inc
Description: 6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Central line with CVP and continuous ScvO2 monitoring
Description: 6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
Study: NCT06276790

Intervention type: PROCEDURE
Intervention: ultrasound-guided/hysteroscopic curettage
Description: ultrasound-guided/hysteroscopic curettage

Intervention type: PROCEDURE
Intervention: Procedure/Surgery: laparoscopic removal of the pregnancy lesion
Description: laparoscopic removal of the pregnancy lesion
Study: NCT03328923

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500mg brown seaweed powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02337166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate
Description: 0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal flap surgery
Study: NCT01640665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
Study: NCT04652674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine visit
Description: A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person postoperative visit
Description: A standard-of-care in-person postoperatively visit with the patient's surgeon
Study: NCT02528357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W